EQS-Media / 13.07.2022 / 12:42
Roggwil, July 13, 2022 – Due to the COVID pandemic, work for the FDA
approval of the tinniwell was stopped at the beginning of 2021. This has
now been resumed and Chief Medical Officer Thomas Rauterkus has been
commissioned to manage the project. The aim is to complete this project
within 12 months and thus gain entry into the medical technology market in
the USA.
We currently assess the market environment as very favorable, since the
only serious competitor, Neuralink, led by the investor Elon Musk,
suffered a serious setback in the FDA approval of its solution. In animal
experiments, brain implants were implanted in monkeys, which, among other
things, were later to cure tinnitus. Many of these experimental animals
have died for a variety of reasons. Elon Musk estimates that the
application will still be available in 5 years.
The management of Resaphene Suisse AG sees the time estimate and the
widespread use of the therapy as unrealistic. Even if Neuralink’s product
were approved, we estimate the cost of the therapy to be in the five to
six-digit dollar range. A reimbursement by health insurance companies is
excluded, as this would completely overwhelm the budget of the insurance
companies due to the large number of tinnitus patients. A private
assumption of costs by the patients themselves will probably only occur in
isolated cases, since most of them simply do not have the financial means.
This means that tinniwell remains the only available tinnitus therapy that
has been proven to cure tinnitus. Due to the unavailability of competing
products with similar performance characteristics, Resaphene Suisse AG
currently holds a monopoly position in tinnitus therapy.
++ Contact for questions:
Resaphene Suisse AG
Mrs. Anke Rauterkus (Chief Executive Officer)
Rütistrasse 8b
9325 Roggwil
Switzerland
T. +41 714500668
[email protected]
End of Media Release
══════════════════════════════════════════════════════════════════════════
Additional features:
Picture:
[1] https://eqs-cockpit.com/c/fncls.ssp?u=a3dceff9548211323c2ae845d6370fde
Subtitle: tinniwell
══════════════════════════════════════════════════════════════════════════
Issuer: Resaphene Suisse AG
Key word(s): Research/Technology
13.07.2022 This Press Release was distributed by EQS Group AG. www.eqs.com
══════════════════════════════════════════════════════════════════════════
1397283 13.07.2022
References
Visible links
1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=db670cb04a101911c9e560928f7357f8&application_id=1397283&site_id=apa_ots_austria&application_name=news
OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender
Der Beitrag Resaphene Suisse AG: FDA approval process for tinnitus therapy tinniwell continues erschien zuerst auf TOP News Österreich – Nachrichten aus Österreich und der ganzen Welt.
